Somagenetix AG secures CHF 10 million in Series A to advance lentiviral gene therapy for Chronic Granulomatous Disease
News 10.10.2024 Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its Series A financing round, raising CHF 10 million. The round was led by Vi Partners, renowned venture capital firm specialized in life sciences and technology investments. Among others, existing...